Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCShugeng Gao, Jie He, Ning Li et al.|Journal of Thoracic Oncology|2020Cited by 415
Global environmental and toxicological data of emerging plasticizers: current knowledge, regrettable substitution dilemma, green solution and future perspectivesAbdul Qadeer, Shuhang Wang, Kun Wang et al.|Green Chemistry|2024Cited by 103
Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLCFan Zhang, Jie He, Wei Guo et al.|Journal of Thoracic Oncology|2022Cited by 74
Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancerBolun Zhou, Shugeng Gao, Fan Zhang et al.|Journal for ImmunoTherapy of Cancer|2024Cited by 8
Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.Shugeng Gao, Jie He, Ning Li et al.|Journal of Clinical Oncology|2021Cited by 5